MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 05-16-2026
Concert Pharmaceuticals Total Liabilities 2011-2026 | CNCE
Annual Total Liabilities Concert Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 53.1 M | 28.1 M | 36 M | 24.8 M | 15.3 M | 14.8 M | 16.3 M | 29.6 M | 39.6 M | 140 M | 136 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 140 M | 14.8 M | 48.5 M |
Quarterly Total Liabilities Concert Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 37.9 M | 48.6 M | 52.8 M | 53.1 M | 29 M | 26 M | 26 M | 28.1 M | 25.4 M | 27.9 M | 32.8 M | 36 M | 32.7 M | 32.9 M | 33.6 M | 24.8 M | 22.8 M | 20.2 M | 17.2 M | 15.3 M | 16.4 M | 44.2 M | 14 M | 14.8 M | 16.2 M | 16.4 M | 15 M | 16.3 M | 17.4 M | 20.5 M | 24.9 M | 29.6 M | 32.7 M | 34 M | 36.4 M | 39.6 M | 39.6 M | 39.6 M | 39.6 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 53.1 M | 14 M | 29 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
6.06 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
6.56 M | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
6.99 M | - | -10.17 % | $ 12.2 K |  USA |
 |
Coherus BioSciences
CHRS
|
197 M | $ 1.73 | 5.18 % | $ 203 M | USA |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M | China |
 |
Celldex Therapeutics
CLDX
|
55.8 M | $ 31.65 | 2.59 % | $ 2.1 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B | France |
 |
BioNTech SE
BNTX
|
2.76 B | $ 94.81 | 2.78 % | $ 22.9 B | Germany |
 |
AstraZeneca PLC
AZN
|
65.4 B | - | - | $ 96.9 B |  Britain |
 |
CRISPR Therapeutics AG
CRSP
|
343 M | $ 53.52 | 3.74 % | $ 4.81 B |  Schweiz |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
64.4 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
71.5 M | - | 0.74 % | $ 768 M |  Israel |
 |
Compugen Ltd.
CGEN
|
18.5 M | $ 2.68 | 1.13 % | $ 250 M | Israel |
 |
Abcam plc
ABCM
|
330 M | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
645 K | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
6.77 M | - | -18.52 % | $ 27.3 M | Britain |
|
Enlivex Therapeutics Ltd.
ENLV
|
392 M | $ 0.78 | 14.04 % | $ 35.6 M | Israel |
 |
Esperion Therapeutics
ESPR
|
768 M | $ 3.13 | 0.32 % | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
66 M | $ 31.66 | 1.18 % | $ 852 M | USA |
 |
Affimed N.V.
AFMD
|
104 M | - | -34.95 % | $ 21.5 M | Germany |
|
Forte Biosciences
FBRX
|
21.8 M | $ 22.13 | 0.87 % | $ 287 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
9.38 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
35.1 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
84 M | - | -7.31 % | $ 87 M | USA |
 |
Galectin Therapeutics
GALT
|
146 M | $ 2.72 | -2.69 % | $ 174 M | USA |
 |
Generation Bio Co.
GBIO
|
145 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
38 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M | Israel |
 |
Grifols, S.A.
GRFS
|
12.8 B | $ 8.08 | 0.9 % | $ 5.49 B |  Spain |
 |
Hutchison China MediTech Limited
HCM
|
502 M | $ 11.72 | -0.26 % | $ 10.1 B | China |
 |
Cyclacel Pharmaceuticals
CYCCP
|
1.34 M | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
34.2 M | - | - | $ 384 M | Britain |
 |
Heron Therapeutics
HRTX
|
242 M | $ 0.9 | 2.13 % | $ 150 M | USA |
 |
Gracell Biotechnologies
GRCL
|
281 M | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
42.3 M | $ 14.76 | -0.87 % | $ 212 M | USA |
 |
Advaxis
ADXS
|
2.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
17.6 M | - | 5.93 % | $ 314 M | Canada |
 |
InflaRx N.V.
IFRX
|
13.7 M | $ 2.6 | -5.11 % | $ 175 M | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
43.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 3.35 | -4.83 % | $ 5.51 M | Israel |